These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 25056464

  • 1. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
    Ghosh S, Chattopadhyay R, Goswami S, Chaudhury K, Chakravarty B, Ganesh A.
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles.
    Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L, Seif S, Baheiraei N.
    Gynecol Endocrinol; 2016 Jul; 32(3):213-7. PubMed ID: 26486011
    [Abstract] [Full Text] [Related]

  • 4. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.
    Tournaye H, Sukhikh GT, Kahler E, Griesinger G.
    Hum Reprod; 2017 May 01; 32(5):1019-1027. PubMed ID: 28333318
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination.
    Taş M, Uludag SZ, Aygen ME, Sahin Y.
    Gynecol Endocrinol; 2020 Jan 01; 36(1):77-80. PubMed ID: 31464143
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial.
    Karakus S, Kiran G, Ciralik H.
    Aust N Z J Obstet Gynaecol; 2009 Dec 01; 49(6):685-8. PubMed ID: 20070724
    [Abstract] [Full Text] [Related]

  • 11. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone.
    Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, Kohl Schwartz AS.
    Front Endocrinol (Lausanne); 2023 Dec 01; 14():1128564. PubMed ID: 36992810
    [Abstract] [Full Text] [Related]

  • 12. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
    Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO, Martins WP, Nakagawa HM.
    JBRA Assist Reprod; 2018 Jun 01; 22(2):148-156. PubMed ID: 29488367
    [Abstract] [Full Text] [Related]

  • 13. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients.
    Ozer G, Yuksel B, Yucel Cicek OS, Kahraman S.
    J Gynecol Obstet Hum Reprod; 2021 May 01; 50(5):102030. PubMed ID: 33271319
    [Abstract] [Full Text] [Related]

  • 14. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone.
    Patki A, Pawar VC.
    Gynecol Endocrinol; 2007 Oct 01; 23 Suppl 1():68-72. PubMed ID: 17943542
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dydrogesterone in the reduction of recurrent spontaneous abortion.
    El-Zibdeh MY.
    J Steroid Biochem Mol Biol; 2005 Dec 01; 97(5):431-4. PubMed ID: 16253504
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dydrogesterone support in threatened miscarriage.
    El-Zibdeh MY, Yousef LT.
    Maturitas; 2009 Dec 01; 65 Suppl 1():S43-6. PubMed ID: 20007011
    [Abstract] [Full Text] [Related]

  • 20. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis.
    Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S, Tournaye H.
    PLoS One; 2020 Dec 01; 15(11):e0241044. PubMed ID: 33147288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.